Skip to main content

Proposed rules

Scheduled rulemaking hearing notices

There are currently no scheduled rulemaking hearings.

Sign up here to receive email notifications of pending DFR rulemaking hearings.

Click on a proposed rule title below for details.

​Rules affected: OAR 441-175-0002

Amended to increase the broker-dealer salesperson license renewal to $60.

ORS 59.175 requires the Director of the Department of Consumer and Business Services to establish fees, related to the Oregon Securities Law, as equal as possible to the national midpoint for similar fees. The statute also provides that every two years the Director may adjust the fees to reflect changes in the national midpoint. The department conducted a survey of state fees related to securities registrations and licensing. It found that the department’s renewal fee for broker-dealer salespersons is $10 lower than the national midpoint. Twenty six states have a broker-dealer salesperson renewal fee of $60 or more. This rulemaking proposes to raise the broker-dealer salesperson license renewal fee by $10 to $60. The proposed rules would also bring the salesperson renewal fee up to the amount of the original licensing fee. Forty-three of the 51 jurisdictions surveyed have the same renewal fee as the initial fee. These rules are necessary and appropriate and consistent with the provisions of ORS 59.175 and the Oregon Securities Law.

Filed: December 19, 2018

Public hearing: January 22, 2019, 11:00 a.m.

Last day for public comment: January 29, 2019, 5 p.m.

Public comments received:



​Rules affected: OAR OAR 836-053-0473, 836-200-0500, 836-200-0505, 836-200-0510, 836-200-0515, 836-200-0520, 836-200-0525, 836-200-0530, 836-200-0535, 836-200-0540, 836-200-0545, 836-200-0550, 836-200-0555, 836-200-0560

Need for Rules:
The Prescription Drug Price Transparency Act (2018 Oregon House Bill 4005, enrolled at 2018 Oregon Laws, Chapter 7) directs the Department of Consumer and Business Services (DCBS) to establish a reporting program for prescription drug manufacturers and health insurance carriers to increase the transparency of prescription drug pricing in Oregon. This program will be known as the Oregon Prescription Drug Price Transparency program. The law directs DCBS to engage in rulemaking to define key terms and timelines, and empowers DCBS to establish fees, adopt a schedule of civil penalties for violations and adopt any other rules necessary for carrying out the provisions of Section 2 of the law.

The proposed rule establishes:

  • Definitions for key terms including “new prescription drug,” “net annual increase,” “one month supply” and “course of treatment” that clarify the circumstances when a report is required;
  • Form, manner and content requirements for reports from drug manufacturers;
  • DCBS’s supervisory expectations of participating drug manufacturers, including good faith standards;
  • Timelines for DCBS to request additional information relating to drug manufacturer reports, and for manufacturers’ responses;
  • DCBS’s process for adjudicating trade secret claims from drug manufacturers;
  • Timelines for DCBS to make drug manufacturer reports publicly available, subject to applicable trade secret exemptions;
  • DCBS’s process for receiving notices from consumers about prescription drug price increases;
  • Establishing an annual $400 fee for drug manufacturers, as well as an additional surcharge fee for manufacturers that file reports with DCBS;
  • Adopting a schedule of civil penalties for drug manufacturer violations; and
  • Requirements for information on drug pricing to be provided by health insurance carriers in rate filings.

The proposed rules are necessary to ensure that the program is administered in a fair and equal manner for all participating drug manufacturers and health insurance carriers, to minimize the administrative burden and cost of the program for the state and the industry, and to achieve the program’s purpose of providing notice and disclosure of information relating to the cost and pricing of prescription drugs in order to provide accountability for prescription drug pricing.

Filed: December 28, 2018

Public hearing: January 22, 2019, 10:00 a.m.

Last day for public comment: February 1, 2019, 5 p.m.

Public comments received



Where to send comments on proposed rules

Division of Financial Regulation

Rulemaking advisory committees

Agency Mailing / Interested Party List:

If you are interested in receiving notices of all Division of Financial Regulation administrative rule changes, please sign-up via the link below and select "Proposed Rules" and "Recently Adopted Rules"

Email notification

This electronic notification service is used to send notifications of all administrative rule changes per ORS 183.335(8). Please note each subscriber must keep their subscription choices and email address up to date to ensure they receive the appropriate notices.

If you have questions or if you need to request hard copy notices, you may contact Karen Winkel via email at

Key links

Oregon Revised Statutes
Oregon Administrative Rules

Your browser is out-of-date! It has known security flaws and may not display all features of this and other websites. Learn how